Nucleoside antiretroviral therapy currently remains the cornerstone of drug therapy of human immunodeficiency virus (HIV) infection. Unfortunately, most of the currently available agents exhibit significant interpatient variability in their pharmacokinetic properties, which leads to variability in in vivo drug exposure (11) . This can result in modulation of the therapeutic as well as the toxicological responses to these agents (3, 4, 9, 13) . For example, the development of opportunistic infections and hematological toxicity has been linked to the mean concentrations of zidovudine in serum (4, 13) , and suppression of p24 antigen and changes in children's intelligence quotient scores have been correlated with didanosine exposure (3, 9) . Careful consideration of the pharmacokinetic properties of drugs and elucidation of the sources of variability are important early in the dose-defining process for future testing in large-scale clinical trials.
Recent emphasis in drug development has been placed on population-based methods for describing the dispositions of drugs in patients. Nonlinear mixed-effects modeling (NONMEM) and nonparametric expectation maximization algorithm (NPEM) are examples of techniques that allow for the estimation of population values of pharmacokinetic parameters along with their variabilities (7, 8, 19) .
Stavudine (d4T; 2Ј,3Ј-didehydro-3Ј-deoxythymidine) is a pyrimidine nucleoside antiretroviral agent with in vitro activity against HIV similar to that of zidovudine (2) . It also appears to retain activity against some zidovudine-resistant strains of HIV (16) . Preclinical and clinical studies have also shown stavudine to be less cytotoxic than zidovudine (1, 5) ; however, the doselimiting toxicity in humans is peripheral neuropathy (6, 18, 21) .
This report summarizes the population pharmacokinetics of stavudine in 81 patients to whom stavudine was administered orally (p.o.) in phase I and phase I/II dose-ranging studies by using nonlinear mixed-effects modeling as implemented in the program NONMEM.
MATERIALS AND METHODS
Patients. Data from three phase I and phase I/II protocols of stavudine were obtained from Bristol-Myers Squibb; the clinical results from those studies have been described elsewhere (6, 18, 20) . The patients enrolled in the protocols were Ն12 years of age and had either AIDS as defined by the Centers for Disease Control and Prevention (CDC) or AIDS-related complex (ARC; CDC stage IV-A or IV-C-2), a CD4 cell count of Յ500/mm 3 , no active AIDS-defining opportunistic infections, and no previous hematological intolerance to zidovudine. In addition to the above, patients had the following characteristics at the time of entry into the study: hemoglobin concentration of Ն8.5 g/liter; neutrophil count of Ն950/mm 3 ; platelet count of Ն75,000/mm 3 ; alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and bilirubin levels less than three times the upper limit of normal; and a serum creatinine level of Յ1.5 mg/dl. All patients gave informed consent according to the guidelines of the respective institutions.
Study design. The allocation of 81 patients among the different regimens of stavudine in the three protocols is provided in Table 1 . Capsules of stavudine for p.o. administration were administered to patients in dosages ranging from 0.1 to 12 mg/kg of body weight per day divided into two, three, or four doses per day. The combined data set represented more than a 100-fold range in daily dosages of stavudine that were fractionated into administration two, three, or four times daily. A single intravenous (i.v.) dose was also given to a subset of patients prior to the p.o. administration of stavudine, thus allowing for estimation of the absolute bioavailability (F) in these patients.
All blood samples were collected as part of pharmacokinetic studies. Pharmacokinetic studies were conducted in an inpatient setting after administration of the first p.o. dose to all 81 patients. Repeat inpatient sampling for pharmacokinetic analysis was performed for 59 (73%) of these patients after a mean of 19 days (range, 8 to 59 days) of stavudine therapy. Thirty-three patients also received a single i.v. dose (one-quarter of the p.o. dose) prior to receipt of the first p.o. dose of stavudine.
Patients were admitted to an inpatient unit the evening prior to administration of the study doses of stavudine and fasted overnight until 2 h following administration of the morning study dose. Blood samples (3 ml) were collected from an indwelling i.v. catheter before and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 h after administration of a p.o. dose in all protocols and up to 12 or 24 h in the phase I studies. The single i.v. dose was delivered via a constant-rate infusion pump over 60 min; blood samples were drawn before the infusion and at 0.25, 0.5, 0.75, 1, 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12 , and 24 h after the start of the infusion. Blood samples were collected in potassium EDTA-containing Vacutainer tubes, placed on ice, and centrifuged at 3,000 ϫ g at 4ЊC within 1 h of collection. The plasma was placed in screw-cap polypropylene tubes, and the tubes were stored at Ϫ90ЊC.
Plasma stavudine concentrations in 71 patients were assayed by a previously described high-pressure liquid chromatography (HPLC) method (14) . The precision of the HPLC assay was Ͻ9% (coefficient of variation ϫ 100%). In patients receiving stavudine at dosages of Յ2 mg/kg/day, a more sensitive radioimmunoassay was used to assay the stavudine concentrations in plasma samples. The total number of samples assayed by this method comprised ca. 10% of the total number of samples. This assay used 10 l of sample combined with 185 l of total of antibody and control plasma. The mixture was combined and was stored overnight at 4ЊC, and then 200 l of 125 I-labeled histamine-stavudine conjugate was added. This mixture was refrigerated at 4ЊC for 4 h; this was followed by the addition of 1 ml of a 7.5% polyethylene glycol solution containing 1% goat anti-rabbit gamma globulin. The samples were then centrifuged, and the supernatant was decanted and discarded. The remaining pellet was resuspended in scintillation fluid to measure the radioactivity. The lower limit of quantitation of the radioimmunoassay was 2.5 ng/ml (standard curve range, 2.5 to 100 ng/ml). Accuracy (as the percent deviation of the nominal value) and precision (as the percent coefficient of variation [CV]) for quality control samples were 5 and 8%, respectively. Selected plasma samples were assayed by both HPLC and radioimmunoassay, and the results obtained by both methods were in agreement (data not shown).
Data sets. A total of 1,742 plasma stavudine concentrations were divided into two data sets. Data on the concentration of drug in plasma for all 81 patients Plasma stavudine concentrations versus time and clinical and demographic data were obtained from databases generated from case report forms supplied by Bristol-Myers Squibb. Plasma stavudine concentrations less than the lower limit of quantitation were not used in this analysis. The translator portion of NONMEM (NM-TRAN) uses data in a specific format in which dosing events at time zero are followed by observation events (i.e., plasma drug concentrations or CD4 cell counts) at relative time points for each individual. The data obtained from Bristol-Myers Squibb were merged with the dosing information and were configured in the NM-TRAN format by using a microcomputer for input into NONMEM.
Pharmacostatistical model. Nonlinear mixed-effects modeling was performed by using NONMEM version 3.0 (double precision, level 1.2) on an International Business Machines ES-9000 computer (19) . This version uses the first-order approximation in generating function evaluations. Program-supplied PRED routines were used. Preliminary runs of several models established that a twocompartment open model with first-order rate constants (K a 's) for absorption and elimination (ADVAN4 TRANS3) was optimal for describing the data. The structural model was parameterized as follows: p.o. clearance divided by F (CL/F); volumes of distribution of the central compartment and at steady-state both divided by F (V 1 /F and V ss /F, respectively); intercompartmental clearance divided by F (Q/F); and K a . Since previous pharmacokinetic studies have shown that the half-life of stavudine is approximately 1.1 h (12), steady-state conditions were assumed to exist in those patients undergoing repeat pharmacokinetic studies following the administration of multiple doses. The same structural model with a separate term for bioavailability (F1) was used for the subset of 33 patients who received both the i.v. and the p.o. formulations of stavudine.
Models for interpatient variability and residual error terms were determined by changes in objective function and the increased precision of the pharmacokinetic parameter estimates. Interpatient variability in CL/F, V ss /F, Q/F, and K a were modeled by using a constant coefficient of variation (proportional) term, or j ϭ Ј j (1 ϩ j ), where j is the estimate or typical value for a pharmacokinetic parameter in the jth individual, Ј j is the predicted pharmacokinetic parameter, and j represents the random difference (with mean ϭ 0 and variance ϭ 2 ) between the true value of the pharmacokinetic parameter for the individual and the value predicted by the pharmacostatistical model.
Since a wide range of stavudine concentrations was observed, the residual error was modeled as having both constant and proportional elements:
where C ij is the observed concentration in serum for the jth individual at time i, CЈ ij is the model-predicted concentration in serum for the jth individual at time i, and ε1 ij and ε2 ij are components of residual error. This design allowed for the model to be additive at low drug concentrations and proportional at higher concentrations. Fits that used models in which residual error was strictly proportional, additive, or exponential were inferior (data not shown).
Model-building procedure. The minimum value of the objective function (Ϫ2 ϫ log likelihood) along with plots of weighted residuals versus predicted concentrations in plasma aided in determination of the appropriate pharmacostatistical models for analysis of the data. After the basic model was constructed, additional fixed effects (i.e., patient characteristics or variables) were introduced into the model on the basis of the selection of variables or outcomes of clinical importance and previous observations with nucleoside antiretroviral agents. Absolute values for patient-specific variables such as total body weight or CD4 count (which reflects the degree of disease progression) were included in the model as follows: TVCL ϭ TVCL ϩ j ⅐ TBW, where TVCL is the typical value of CL/F, TBW is the total body weight, and j is the factor value for each individual with a known total body weight.
Nominal data describing patient characteristics and categories were fashioned with if-then statements; for example, the effect of oral stavudine doses greater than 200 mg on CL/F would be coded as follows: if mg Ն200 then TVCL ϭ TVCL ⅐ 1 , where absolute oral doses of Ն200 mg result in a different estimation of CL/F for patients receiving large oral doses.
The criterion for acceptance of a factor into the model was a decrease in the minimum value of the objective function of Ͼ3.8 following introduction of a single term (degrees of freedom ϭ 1), and it was considered statistically significant at the 5% (P Ͻ 0.05) level by using the 2 distribution (17, 19) . A fixed effect was retained in the model as a weight on a particular variable if the minimum objective function decreased significantly and if the 95% confidence intervals (CIs) for the estimate did not include the null value. If the minimum objective function decreased significantly but the 95% CI for the estimate included the null value, the effect of the variable was considered to be of borderline significance and it was not retained in the final model. Plots of weighted residuals versus predicted concentrations in plasma or variables also guided the selection of fixed effects for inclusion and retention in the model during the model-building procedure.
Single variables that were found to significantly improve the fit of the model to the data were tested together to develop the final model. In order to eliminate covariates, each variable was taken out of the model by setting it equal to its null value. A change in the minimum objective function of Ͼ3.8 signified that the variable was important and it was retained in the final model.
RESULTS
The characteristics of the 81 patients included in the analysis are given in Table 2 . The population consisted largely of white men in their mid-30s who acquired HIV through homosexual or heterosexual transmission. Most patients had ARC, with the median CD4 cell count being less than 200 cells per mm 3 upon entry into the study. Approximately half of the patients had received previous zidovudine therapy for various intervals. The range of measurable plasma stavudine concentrations ranged between 0.0025 and 7.5 g/ml.
Basic model. The pharmacokinetic parameter estimates obtained with the basic model are given in Table 3 . The CL of stavudine given p.o. was estimated to be ϳ31 liters/h, with interpatient variability estimated to be 24.5%. The decline in plasma stavudine concentrations as described by a two-compartment model was evident by estimation of a peripheral compartment (represented by V ss /F Ϫ V 1 /F) about sevenfold larger than that of the central compartment. The absorption rate of stavudine given p.o. was typically rapid, with a high estimate for interpatient variability. Interpatient variability (expressed as percent CV) for V ss /F and Q/F were 105 and 26%, respectively. The CV for residual error was estimated to be ϳ41% for the range of plasma stavudine concentrations measured.
Results of the analysis of data for the subset of 33 patients who received stavudine both i.v. and p.o. (i.v./p.o. data set) are given in Table 4 . The estimate of absolute F was 99.1%, with an interpatient variability of 18.5% (CV). When all data for the patients who received stavudine by the p.o. and i.v. routes were analyzed together (i.e., levels in plasma of all 81 patients given drug by the i.v. and p.o. routes), the estimate of F was similar to this value (data not shown). The estimates of CL and V ss for this subset of patients were similar to those obtained with the full (p.o.) data set. Estimates of V 1 and Q (after accounting for F) were different for this subset of 33 patients compared with those for all 81 patients, likely because of improved estimation of values for these parameters with the availability of plasma samples collected during the i.v. infusion.
Model building. The patient characteristics and variables (fixed effects) tested individually for inclusion in the model of CL/F for the p.o. data set are given in Table 5 . The fixed effects found singly to significantly influence the estimates of CL/F were p.o. stavudine doses of Ն200 mg, total body weight, a diagnosis of AIDS, receipt of prior zidovudine therapy, and calculated lean body weight. However, the 95% CIs for the magnitude of the effect for the latter two factors included the null value. Models that used different stavudine dose breakpoints (e.g., Ն150 mg) had no effect on estimates of CL. Therefore, only a p.o. stavudine dose of Ն200 mg, total body weight, and a diagnosis of AIDS versus ARC were tested further in the full model.
The fixed effects found to significantly influence the estimates of V ss /F were total body weight and calculated lean body weight. Although statistically significant, the 95% CI for estimates of the magnitude of the effect of lean body weight included the null value (as it did with the CL of drug given p.o.), and therefore it was not included in the full model. Final model. The parameter estimates generated in the final model are given in Table 6 . The final model included terms for total body weight, stage of HIV infection (AIDS versus ARC), and receipt of a high dose (Ն200 mg per dose) of stavudine. Figure 1 shows the plasma stavudine concentrations in a 70-kg patient with AIDS or ARC. Total body weight in the estimation of V ss /F was dropped from the full model because its effect became statistically insignificant when all factors were included in the final model for CL/F. When the parameters for high p.o. stavudine doses, total body weight, and AIDS were individually restricted to their null values, significant increases (141, 25, and 13, respectively) in the minimum objective function resulted. Therefore, all three fixed effects were retained within the final model for the CL of stavudine given p.o.: CL/F ϭ (18.8 ϩ 0.13 ⅐ TBW) ⅐ (1.2 Ϫ stage) ⅐ (1.5 Ϫ dose), where CL/F is in liters per hour, TBW is total body weight in kilograms, stage is 0.2 if the patient has ARC and 0 if the patient has AIDS, and dose is 0.5 if the patient ingests a p.o. dose of Ͻ200 mg and 0 if the patients ingests a p.o. dose of Ն200 mg. The estimates of V 1 /F, V ss /F, Q/F, and K a and their respective CIs were essentially unchanged from those from the basic model, as were the estimates of interpatient variability. Residual error was also unchanged from that from the basic model. A comparison of the plots of weighted residuals versus predicted plasma stavudine concentrations in the basic and final models showed some improvement for the predicted plasma stavudine concentrations in the higher range (Fig. 2) .
DISCUSSION
Therapy of HIV infection with currently available nucleoside antiretroviral agents is frequently frustrated by a high degree of variability between patients in in vivo drug exposure following the administration of fixed doses of drug. This is particularly problematic for zidovudine, for which there may be more than a 10-fold range in the area under the concentration-time curve among patients because of differences in the F and CL of the drug (11). The differences in drug exposure may have a marked impact on the observed antiviral effects, as well as the tolerance to drug during therapy (9) (10) (11) . Therefore, development of newer nucleosides with improved F and a low degree of interpatient variability would be desirable in the long-term management of patients with HIV infection.
The present study extends previous observations concerning This analysis identified patient characteristics associated with the population estimate of CL of drug given p.o. Information on total body weight, the diagnosis of AIDS (versus ARC), and p.o. stavudine doses of Ն200 mg statistically improved the population model for CL/F (see final model). The increase in stavudine CL/F with the higher dose is consistent with trends reported previously and suggests a slightly lower F of drug given p.o. at higher doses. Reduction in the F values of certain nucleosides given p.o. has previously been attributed to saturation of carrier-mediated transport of drug across the gastrointestinal mucosa (10, 11, 15) .
Although inclusion of some fixed effects resulted in a statistically significant improvement in the model, it appears that some of these associations are of limited clinical significance. The change in the CL of stavudine given p.o. with higher doses is of limited clinical importance since dose-limiting peripheral neuropathy precludes the use of daily exposures associated with this dose, and lower doses have been shown to have acceptable tolerance with clinical benefit (20) . The difference in CL/F between patients with AIDS and those with ARC was small. As shown in Fig. 1 , there is much overlap between the serum stavudine concentrations was for typical patients with either AIDS or ARC. Similarly, the effect that total body weight had on stavudine CL/F was of small magnitude; only a 15% variation in the base value of the CL of drug given p.o. (calculated by using the median total body weight of 70 kg for the 81 patients) occurred for the upper and lower extremes of the total body weight in patients enrolled in these studies. These data suggest that stavudine doses do not need to be adjusted for total body weight in adult patients weighing between 40 and 100 kg. However, in patients with AIDS with a combination of extreme values in body weight, dose individualization may be required to achieve maximal antiviral effects.
This analysis represents one of the most comprehensive evaluations of the pharmacokinetics of an antiretroviral agent in target populations prior to widespread use of the drug. The results show that intersubject variability in the major pharmacokinetic parameters for stavudine that influence systemic exposure (i.e., CL of drug given p.o. and the area under the concentration-time curve) is low. Low variability in CL/F between patients suggests that dose is an acceptable controller for exposure to stavudine in vivo. Further studies to evaluate stavudine pharmacokinetics over more prolonged periods of therapy are in progress. 
